TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00367276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)
Description: Yasmin, SH T 470 FA; 30 µg ethinylestradiol and 3 mg drospirenone, oral administration over 6 treatment cycles, one tablet per day for 21 days followed by a 7 day pill-free interval.
Study: NCT03677297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel
Study: NCT03848767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AID System
Description: AID System

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Individualized doses of insulin lispro administered via the AID system to maintain glycemic control except during meal challenges.
Study: NCT03305393

Intervention type: DEVICE
Group type: OTHER
Intervention: Adaptiv CRT
Description: Adaptiv CRT algorithm to be programmed to ON in CRT devices of study patients at 6 month follow-up visit
Study: NCT02579681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: dimethyl fumarate administered as per the arm description
Study: NCT04890015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative transanal decompression tube placement
Description: Intraoperatively under direct vision in the lower rectum, the balloon of the catheter will be inflated with 5-10cc of distilled water and it will be secured with a dressing / tape to the buttock connected to a collection bag.
Study: NCT03782441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype 0.5
Description: Investigational Medical Device collecting spectral Raman data from tissue
Study: NCT01812512

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF
Description: The curriculum plan adapts components from the Rochester Participatory Decision-Making Scale (RPAD) and recent advances in communication skills training for chronic disease to develop a valid and reliable intervention specific to Home Telehealth (HT) shared decision making, effective telehealth communication, and patient self-management for heart failure (HF), using established best-practices and Veteran input. Veteran volunteers will participate in video recorded simulations to promote nurse care coordinator (NCC) active participation and problem-solving during the course. Scenarios are taken from transcribed actual HT interactions from the first exploratory RRP study of HT. The course is set up as one live session, one online module, and a final live session for more difficult conversations.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF
Description: The curriculum plan adapts components from the Rochester Participatory Decision-Making Scale (RPAD) and recent advances in communication skills training for chronic disease to develop a valid and reliable intervention specific to Home Telehealth (HT) shared decision making, effective telehealth communication, and patient self-management for heart failure (HF), using established best-practices and Veteran input. Veteran volunteers will participate in video recorded simulations to promote nurse care coordinator (NCC) active participation and problem-solving during the course. Scenarios are taken from transcribed actual HT interactions from the first exploratory RRP study of HT. The course is set up as one live session, one online module, and a final live session for more difficult conversations.
Study: NCT00521664

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic platelet transfusion
Description: In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic platelet transfusion
Description: In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
Study: NCT03987386

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo conventional radiation therapy
Study: NCT01137253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethaphan
Description: Trimethaphan 4 mg/min IV, for the duration of the study (approximately 2 hours)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Response to intrabrachial vasodilators during IV saline infusion
Study: NCT01317511

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein
Description: Protein drink

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Protein drink
Study: NCT05643586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patient treated with 180 mg ticagrelor 12 hours before the procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Patient treated with 60 mg prasugrel 12 hours before the procedure
Study: NCT03550768

Intervention type: OTHER
Intervention: MDP
Description: evaluate the anatomy of each major duodenal papilla before selective cannulation during ERCP
Study: NCT04634942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryos REF 0971 Cold Spray
Description: Cold Spray Coolant spray is manufactured from liquefied gases with high pressure. It acts by rapidly reducing the temperature in the body area where it is applied. The liquefied gas in the tube spreads on the skin in liquid form and takes the heat of the skin by turning into gas. The temperature of the area where it is applied drops from 30-32 degrees to 10-15 degrees. With the effect of the cold, the excitability of the nerve endings decreases, and thus the pain on the skin is felt by the person. Cold sprays, whose analgesic effect occurs immediately, are applied parallel to the muscle fibers in the area to be applied, from a distance of 15-45 centimeters, by squeezing for approximately 5-15 seconds. Cold sprays are suitable for long-term and multiple uses.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cryos REF 0971 Cold Spray
Description: Cold Spray Coolant spray is manufactured from liquefied gases with high pressure. It acts by rapidly reducing the temperature in the body area where it is applied. The liquefied gas in the tube spreads on the skin in liquid form and takes the heat of the skin by turning into gas. The temperature of the area where it is applied drops from 30-32 degrees to 10-15 degrees. With the effect of the cold, the excitability of the nerve endings decreases, and thus the pain on the skin is felt by the person. Cold sprays, whose analgesic effect occurs immediately, are applied parallel to the muscle fibers in the area to be applied, from a distance of 15-45 centimeters, by squeezing for approximately 5-15 seconds. Cold sprays are suitable for long-term and multiple uses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShotBlocker BIONIX Press Firmly USA
Description: ShotBlocker ShotBlocker is a plastic tool with a small and flat shape, with short and non-sharp protrusions on one side that connect with the skin. It resembles a horseshoe (C shaped) with its structure designed to expose the area to be injected. It is suitable for all age groups. It does not have any side effects. ShotBlocker can be used for both intramuscular and subcutaneous injections. The protruding surface of the ShotBlocker is held by pressing the skin during the injection and the process is performed from the part where the opening is.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ShotBlocker BIONIX Press Firmly USA
Description: ShotBlocker ShotBlocker is a plastic tool with a small and flat shape, with short and non-sharp protrusions on one side that connect with the skin. It resembles a horseshoe (C shaped) with its structure designed to expose the area to be injected. It is suitable for all age groups. It does not have any side effects. ShotBlocker can be used for both intramuscular and subcutaneous injections. The protruding surface of the ShotBlocker is held by pressing the skin during the injection and the process is performed from the part where the opening is.
Study: NCT03583736

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual visit
Description: Virtual visit with oncologist following uterine cancer diagnosis prior to scheduled office visit.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Office visit
Description: Scheduled office visit with oncologist following uterine cancer diagnosis.
Study: NCT02372422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound determination of cervical length
Description: Transvaginal ultrasound was used to measure the length of the cervix from the internal to external os relying on a standard approach and clinicians caring for the patients were made aware of the results.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine care
Description: Routine prenatal care of twins. Digital exams were permitted, but transvaginal ultrasound assessment of cervical length was not.
Study: NCT01059383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VECAM 40/300
Description: 1 capsule, orally, once daily at bedtime.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 20 mg
Description: 1 capsule, orally, once daily 30-60 min. before dinner
Study: NCT02830620

Intervention type: OTHER
Group type: OTHER
Intervention: Dosage of chimiokines

Intervention type: OTHER
Group type: OTHER
Intervention: Dosage of chimiokines

Intervention type: OTHER
Group type: OTHER
Intervention: Dosage of chimiokines

Intervention type: OTHER
Group type: OTHER
Intervention: Dosage of chimiokines
Study: NCT00516035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
Description: Vaccine given by nasal spray
Study: NCT02332824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-272 Placebo
Description: TAK-272 placebo-matching tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan cilexetil
Description: Candesartan cilexetil tablets
Study: NCT03044184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Transamine is an antifibrinolytic medication given systemically via the intravenous route
Study: NCT03230292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab will be administered subcutaneously in 2 different doses.
Study: NCT00490620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination antiviral therapy
Description: Zidovudine 300mg and lamivudine 150mg BID for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo BID for 6 months
Study: NCT00820872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study: NCT02332824

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Candesartan cilexetil Placebo
Description: Candesartan cilexetil placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil Placebo
Description: Candesartan cilexetil placebo-matching tablets
Study: NCT00820872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT01526265

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Rewards
Description: If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed Deposits
Description: Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competitive Deposits (Pari-Mutuel)
Description: Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Rewards
Description: Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking.
Study: NCT03676322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive single ascending oral dose of M5049 in Part A. Participants will receive multiple ascending oral dose of M5049 once daily for 14 days or twice daily for 13 days followed by a single dose on Day 14 in the morning in Part B. Participants will receive a single oral dose of M5049 under fed conditions in Part C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive single ascending oral dose of M5049 in Part A. Participants will receive multiple ascending oral dose of M5049 once daily for 14 days or twice daily for 13 days followed by a single dose on Day 14 in the morning in Part B. Participants will receive a single oral dose of M5049 under fed conditions in Part C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive single ascending oral dose of M5049 in Part A. Participants will receive multiple ascending oral dose of M5049 once daily for 14 days or twice daily for 13 days followed by a single dose on Day 14 in the morning in Part B. Participants will receive a single oral dose of M5049 under fed conditions in Part C.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to M5049.
Study: NCT02332824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil Placebo
Description: Candesartan cilexetil placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil Placebo
Description: Candesartan cilexetil placebo-matching tablets
Study: NCT03406806

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SprintSystem device
Description: The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIH toolbox 4 meter walk
Description: The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System \[6\] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet.
Study: NCT01342627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to the protocol.~In case of disease progression Sorafenib administration will be discontinued.
Study: NCT02332824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil Placebo
Description: Candesartan cilexetil placebo-matching tablets
Study: NCT04749797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Used as cranial block for craniotomy surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: Used as cranial block for craniotomy surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Used as cranial block for craniotomy surgery
Study: NCT00828178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: Omega-3-acid ethyl esters (Lovaza) 3 gram once a day for 12 weeks
Study: NCT03740373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold
Description: Participants will receive a single dose of BGF MDI; the dose will be administered with a 10 s breath-hold.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold
Description: Participants will receive a single dose of BGF MDI; the dose will be administered with a 10 s breath-hold.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold
Description: Participants will receive a single dose of BGF MDI; the dose will be administered with a 3 s breath-hold.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold
Description: Participants will receive a single dose of BGF MDI; the dose will be administered with a 3 s breath-hold.
Study: NCT02477631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: This is a single-arm, open-label, multi-center study in 20 patients with MDS. All participants will be treated with deferiprone for up to 4 months.
Study: NCT02452034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole IV solution
Description: Posaconazole by IV solution twice on Day 1, then once daily on Days 2-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole IV solution
Description: Posaconazole by IV solution twice on Day 1, then once daily on Days 2-10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole IV solution
Description: Posaconazole by IV solution twice on Day 1, then once daily on Days 2-10.
Study: NCT00828178

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: flow-mediated dilation of the brachial artery
Description: flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: flow-mediated dilation of the brachial artery
Description: flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: corn starch
Description: 3 capsules qd for 12weeks
Study: NCT00632736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole XL (formerly CR)
Study: NCT01790100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-135
Description: 12 weeks of VX-135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-135
Description: 12 weeks of VX-135
Study: NCT00820872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Study: NCT01790100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 12 weeks of ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 12 weeks of ribavirin